MEDICINE DETAILS
Inbrija
Active ingredient: Levodopa
Neutral reference profile for an independent medicine-access consultancy enquiry about Inbrija (Levodopa). No medicine is offered for sale.
NEXT STEP
Choose the strength and pack
✓ If you are unsure, choose “I do not know”.
These options are not medical advice, a dosing recommendation, stock confirmation or a sale offer.
ABOUT THIS MEDICINE
What is Inbrija used for?
Inbrija (levodopa) is an aromatic amino acid indicated for the treatment of Parkinson’s disease. It is used to treat symptoms during ‘off’ periods (times when the patient has more difficulty moving about) that occur while the patient is taking their usual treatment of a combination of carbidopa and levodopa. It does not replace regular carbidopa/levodopa therapy.
It is available in capsule form containing 42 mg Inbrija (levodopa) inhalation powder. Inbrija is the first inhalable formulation of levodopa and can quickly relieve Parkinson’s symptoms.
This information is general and is not medical advice. Talk to your doctor or pharmacist about any treatment decision.
RECORDED PRODUCT PROFILE
Inbrija identity, dosage form and pack information.
The details below are assembled from current catalogue records. They must still be checked against the prescription, medicine box and an official regulatory record.
Recorded strength and pack options
Each row is shown only to help identify the product; it is not stock confirmation or a sale offer.
-
33 mg · 60 bottles Catalogue organisation: Merz Therapeutics GmbH
OFFICIAL SOURCES
Check the Inbrija record at an official source.
Search for “Inbrija” or “Levodopa”. Finding a product in one source does not by itself confirm stock, authorisation in a particular country or suitability for a patient.
OFFICIAL EXTERNAL SOURCE
European Medicines Agency (EMA)
Search medicines evaluated by EMA by brand name or active substance. EMA also links to national registers for nationally authorised products.
↗ OFFICIAL EXTERNAL SOURCE Drugs@FDASearch FDA-approved human drug records by brand name or active ingredient, including current labelling where available.
↗SERVICE BOUNDARY
Information checking and independent enquiry support for Inbrija.
OrphanDrug helps organise the product identity and recorded strength and pack details for an enquiry. It does not sell, take payment for, prescribe, import, dispense or deliver medicines.
Clinical decision: Only a qualified healthcare professional who has assessed the patient can decide whether a product, form or dose is appropriate.
CLEAR ANSWERS
Frequently asked questions about Inbrija
01What is Inbrija?＋
This directory record associates the brand name Inbrija with the active ingredient Levodopa. The brand and ingredient are shown for product identification only, not as treatment or dosing advice.
02Which Inbrija strengths and packs are recorded?＋
The catalogue currently shows: 33 mg · 60 bottles. Check the complete strength, dosage form and pack description against the prescription and medicine box.
03Who manufactures Inbrija?＋
Catalogue records currently name: Merz Therapeutics GmbH. This field may identify a manufacturer, marketing-authorisation holder, marketing company or supplier; confirm the exact role on the pack leaflet and official regulatory record.
04Do the listed options confirm stock or access?＋
No. A catalogue record does not confirm current stock, authorisation in a particular country, clinical suitability, import permission or access.
05What affects a possible estimated medicine cost for Inbrija?＋
A possible cost depends on the exact strength, dosage form, pack, quantity, destination and regulatory jurisdiction. Any amount provided after an enquiry is an indicative medicine-cost estimate only, not a selling price for Inbrija, payment request, stock guarantee or binding offer.
06Can I buy Inbrija from this website?＋
No. This website does not sell, take payment for, prescribe, import, dispense or deliver medicines. The form creates an independent consultancy enquiry only.